Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?

Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis

TNIK in disease: from molecular insights to therapeutic prospects

Advancements in Tyrosine Kinase-Mediated Regulation of Innate Nucleic Acid Sensing.

Pleiotropic functions of TAO kinases and their dysregulation in neurological disorders

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors

TNIK's emerging role in cancer, metabolism, and age-related diseases

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products

Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?

Abnormal phosphorylation of protein tyrosine in neurodegenerative diseases

TNIK’s Emerging Role in Cancer, Metabolism, and Age-Related Diseases

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Autoimmune complications of tyrosine kinase inhibitors in cancer therapy: Clinical insights, mechanisms, and future perspectives

Tyrosine kinase inhibitors and atherosclerosis: A close but complicated relationship

Targeting Tumour Microenvironment by Tyrosine Kinase Inhibitor

Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.